Eterna Therapeutics Inc. logo

Eterna Therapeutics Inc. (ERNA)

Market Closed
12 Dec, 20:00
NASDAQ (CM) NASDAQ (CM)
NASDAQ (CM) NASDAQ (CM) Primary
$
1. 34
-0.14
-9.46%
$
10.83M Market Cap
- P/E Ratio
0% Div Yield
30,579 Volume
0 Eps
$ 1.48
Previous Close
Day Range
1.34 1.47
Year Range
1.09 14.4
Want to track ERNA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

ERNA closed yesterday lower at $1.34, a decrease of 9.46% from Thursday's close, completing a monthly increase of 3.08% or $0.04. Over the past 12 months, ERNA stock lost -71.85%.
ERNA is not paying dividends to its shareholders.
The last earnings report, released on Nov 11, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Eterna Therapeutics Inc. has completed 4 stock splits, with the recent split occurring on Jun 12, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

ERNA Chart

No Data

Similar

CTSO
Cytosorbents Corporation
$ 0.65
-8.87%
ALVR
Kalaris Therapeutics, Inc.
$ 9.81
+4.14%
CUE
Cue Biopharma Inc.
$ 0.48
-2.27%
MDAI
Spectral AI Inc.
$ 1.6
-6.69%
ICCM
IceCure Medical Ltd.
$ 0.67
-3.5%

Eterna Therapeutics Inc. (ERNA) FAQ

What is the stock price today?

The current price is $1.34.

On which exchange is it traded?

Eterna Therapeutics Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is ERNA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 10.83M.

Has Eterna Therapeutics Inc. ever had a stock split?

Eterna Therapeutics Inc. had 4 splits and the recent split was on Jun 12, 2025.

Eterna Therapeutics Inc. Profile

Biotechnology Industry
Healthcare Sector
Sanjeev Luther CEO
NASDAQ (CM) Exchange
114082308 CUSIP
US Country
6 Employees
- Last Dividend
12 Jun 2025 Last Split
19 Oct 1992 IPO Date

Overview

Eterna Therapeutics Inc. is an innovative life science company, established in 2018 and headquartered in Cambridge, Massachusetts. Specializing in mRNA cell engineering technologies, Eterna is at the forefront of developing solutions for cell reprogramming and gene editing. Through a strategic license agreement with Factor Bioscience Limited, Eterna Therapeutics leverages cutting-edge research to pave the way for advancements in genetic therapies and biotechnology.

Products and Services

  • mRNA Cell Reprogramming and Gene Editing

    • This core technology offered by Eterna Therapeutics revolutionizes how scientists approach genetic manipulation, enabling precise alterations in the genetic makeup of cells. It is foundational for developing treatments for genetic disorders and advancing regenerative medicine.

  • NoveSlice and UltraSlice Gene-Editing Proteins

    • Eterna's proprietary gene-editing proteins, NoveSlice and UltraSlice, represent groundbreaking tools in the field of genome editing. These proteins allow for highly efficient and targeted modifications of DNA, providing a robust platform for therapeutic development and biomedical research.

  • ToRNAdo mRNA Delivery System

    • The ToRNAdo mRNA Delivery System is a state-of-the-art technology developed by Eterna for the efficient delivery of mRNA therapeutics. This system ensures that mRNA can be delivered to target cells with high efficacy, a crucial aspect for the success of mRNA-based therapies.

Contact Information

Address: 10355 Science Center Drive
Phone: 212 582 1199
Affiliate Program About Terms Privacy Help Contact Us
2025 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark